OLMA - Company ID 0001750284
Olema Pharmaceuticals, Inc. trades as OLMA and has a market capitalization of $1.07 B, making it the #2594 largest US-listed company by market value. This page tracks Olema Pharmaceuticals, Inc. through 532 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-10
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| Major company event | 8-K | 2026-05-21 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Major company event | 8-K | 2026-05-01 |
| Insider trade | 4 | 2026-04-29 |
| New insider ownership | 3 | 2026-04-29 |
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology – Better medicines for breast cancer and beyond – Olema Oncology Reports First Quarter 2026 Financial and Operating Results
The largest companies sharing Olema Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Olema Pharmaceuticals, Inc. (OLMA) has a market capitalization of $1.07 B as of 2026-07-10, ranking #2594 among US-listed companies.
In its latest fiscal year Olema Pharmaceuticals, Inc. reported a net loss of $162.45M.